Kawartha Cardiology Clinical Trials
Peterborough, Ontario, Canada
Cardiologist in Peterborough, Ontario
327 Charlotte St, Peterborough, ON K9J 0B2
About Kawartha Cardiology Clinical Trials
"Kawartha Cardiology’s mission is to provide comprehensive, integrated services focused on the diagnosis, management, treatment and education of cardiovascular health and rehabilitation."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Pfizer
5
Boehringer Ingelheim
3
Bayer
2
Amgen
1
Brigham and Women's Hospital
1
Eisai Inc.
1
Eli Lilly and Company
1
Idorsia Pharmaceuticals Ltd.
1
Kowa Research Institute, Inc.
1
Clinical Trials at Kawartha Cardiology Clinical Trials
During the past decade, Kawartha Cardiology Clinical Trials conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 9 clinical trials were completed, i.e. on
average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-03-22
Terminated
16,784
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-04-03
Terminated
10,564
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
2014-01-24
2018-05-14
Completed
14,673
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
2014-10-28
2017-07-10
Completed
746
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
2014-06-01
2015-11-01
Completed
184
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
2014-07-22
2017-06-05
Completed
2,725
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
2017-03-02
2021-04-26
Completed
5,988
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Kawartha Cardiology Clinical Trials" #1 sponsor was "Pfizer" with 5 trials, followed by "Boehringer Ingelheim" with 3 trials
sponsored, "Bayer" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Brigham and Women's Hospital"
with 1 trials sponsored. Other sponsors include -1 different institutions and
companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Kawartha Cardiology Clinical Trials"
#1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Kawartha Cardiology Clinical Trials
According to Clinical.Site data, the most researched conditions in "Kawartha Cardiology Clinical Trials" are
"Cardiovascular Disease" (4 trials), "Heart Failure" (3 trials), "Atrial Fibrillation" (2 trials), "Hyperlipidemia" (2 trials) and "Acute Myocardial Infarction" (1 trials). Many other conditions were trialed in "Kawartha Cardiology Clinical Trials" in a lesser frequency.
Clinical Trials Intervention Types at Kawartha Cardiology Clinical Trials
Most popular intervention types in "Kawartha Cardiology Clinical Trials" are "Drug" (15 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (12 trials), "Empagliflozin" (2 trials), "bococizumab (PF-04950615)" (2 trials), "ARRY-371797 (PF-07265803)" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Kawartha Cardiology Clinical Trials
The vast majority of trials in "Kawartha Cardiology Clinical Trials" are
16 trials for "All" genders.
Clinical Trials Status at Kawartha Cardiology Clinical Trials
Currently, there are NaN active trials in "Kawartha Cardiology Clinical Trials".
undefined are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 7 completed trials in Kawartha Cardiology Clinical Trials,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Kawartha Cardiology Clinical Trials, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".